BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the upcoming presentation of detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. Results from the ...
– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback